Friberg LE - Search Results

1

Pharmacokinetic/pharmacodynamic modelling in oncological drug development.

Karlsson MO, Anehall T, Friberg LE, Henningsson A, Kloft C, Sandström M, Xie R. Karlsson MO, et al. Among authors: friberg le. Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):206-11. doi: 10.1111/j.1742-7843.2005.pto960310.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15733216 Free article. Review.

2

Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.

Friberg LE, Freijs A, Sandström M, Karlsson MO. Friberg LE, et al. J Pharmacol Exp Ther. 2000 Nov;295(2):734-40. J Pharmacol Exp Ther. 2000. PMID: 11046112

3

Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats.

Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Freijs A, Hansen K, Larsson R. Jonsson E, et al. Among authors: friberg le. Cancer Chemother Pharmacol. 2000;46(6):493-500. doi: 10.1007/s002800000181. Cancer Chemother Pharmacol. 2000. PMID: 11138463

4

In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients.

Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Nygren P, Kristensen J, Tholander B, Binderup L, Larsson R. Jonsson E, et al. Among authors: friberg le. Cancer Lett. 2001 Jan 26;162(2):193-200. doi: 10.1016/s0304-3835(00)00661-3. Cancer Lett. 2001. PMID: 11146225

5

Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).

Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ. Friberg LE, et al. Eur J Clin Pharmacol. 2000 Nov;56(8):567-74. doi: 10.1007/s002280000181. Eur J Clin Pharmacol. 2000. PMID: 11151746

6

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Friberg LE, et al. J Clin Oncol. 2002 Dec 15;20(24):4713-21. doi: 10.1200/JCO.2002.02.140. J Clin Oncol. 2002. PMID: 12488418

7

Mechanistic models for myelosuppression.

Friberg LE, Karlsson MO. Friberg LE, et al. Invest New Drugs. 2003 May;21(2):183-94. doi: 10.1023/a:1023573429626. Invest New Drugs. 2003. PMID: 12889739 Review.

8

Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model.

Friberg LE, Hassan SB, Lindhagen E, Larsson R, Karlsson MO. Friberg LE, et al. Eur J Pharm Sci. 2005 May;25(1):163-73. doi: 10.1016/j.ejps.2005.02.006. Eur J Pharm Sci. 2005. PMID: 15854812

9

Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.

Friberg LE, Isbister GK, Duffull SB. Friberg LE, et al. Br J Clin Pharmacol. 2006 Feb;61(2):177-90. doi: 10.1111/j.1365-2125.2005.02546.x. Br J Clin Pharmacol. 2006. PMID: 16433872 Free PMC article.

10

A tool for neutrophil guided dose adaptation in chemotherapy.

Wallin JE, Friberg LE, Karlsson MO. Wallin JE, et al. Among authors: friberg le. Comput Methods Programs Biomed. 2009 Mar;93(3):283-91. doi: 10.1016/j.cmpb.2008.10.011. Epub 2008 Dec 11. Comput Methods Programs Biomed. 2009. PMID: 19084287

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

184 results

Search Page